DexCom Earnings Estimate
| DXCM Stock | USD 69.89 0.93 1.31% |
DexCom Earnings Estimation Breakdown
The calculation of DexCom's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of DexCom is estimated to be 0.4762 with the future projection ranging from a low of 0.3957 to a high of 0.55. Please be aware that this consensus of annual earnings estimates for DexCom Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.40 Lowest | Expected EPS | 0.55 Highest |
DexCom Earnings Projection Consensus
Suppose the current estimates of DexCom's value are higher than the current market price of the DexCom stock. In this case, investors may conclude that DexCom is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and DexCom's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 29 | 82.64% | 0.0 | 0.4762 | 1.78 |
DexCom Earnings per Share Projection vs Actual
Actual Earning per Share of DexCom refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering DexCom Inc predict the company's earnings will be in the future. The higher the earnings per share of DexCom, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.DexCom Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as DexCom, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of DexCom should always be considered in relation to other companies to make a more educated investment decision.DexCom Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact DexCom's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-10-30 | 2025-09-30 | 0.57 | 0.61 | 0.04 | 7 | ||
2025-07-30 | 2025-06-30 | 0.44 | 0.48 | 0.04 | 9 | ||
2025-05-01 | 2025-03-31 | 0.33 | 0.32 | -0.01 | 3 | ||
2025-02-13 | 2024-12-31 | 0.48 | 0.38 | -0.1 | 20 | ||
2024-10-24 | 2024-09-30 | 0.43 | 0.45 | 0.02 | 4 | ||
2024-07-25 | 2024-06-30 | 0.39 | 0.43 | 0.04 | 10 | ||
2024-04-25 | 2024-03-31 | 0.27 | 0.32 | 0.05 | 18 | ||
2024-02-08 | 2023-12-31 | 0.43 | 0.5 | 0.07 | 16 | ||
2023-10-26 | 2023-09-30 | 0.34 | 0.5 | 0.16 | 47 | ||
2023-07-27 | 2023-06-30 | 0.23 | 0.34 | 0.11 | 47 | ||
2023-04-27 | 2023-03-31 | 0.15 | 0.17 | 0.02 | 13 | ||
2023-02-09 | 2022-12-31 | 0.27 | 0.34 | 0.07 | 25 | ||
2022-10-27 | 2022-09-30 | 0.24 | 0.28 | 0.04 | 16 | ||
2022-07-28 | 2022-06-30 | 0.19 | 0.17 | -0.02 | 10 | ||
2022-04-28 | 2022-03-31 | 0.13 | 0.08 | -0.05 | 38 | ||
2022-02-10 | 2021-12-31 | 0.21 | 0.17 | -0.04 | 19 | ||
2021-10-28 | 2021-09-30 | 0.16 | 0.22 | 0.06 | 37 | ||
2021-07-29 | 2021-06-30 | 0.11 | 0.19 | 0.08 | 72 | ||
2021-04-29 | 2021-03-31 | 0.07 | 0.08 | 0.01 | 14 | ||
2021-02-11 | 2020-12-31 | 0.23 | 0.23 | 0.0 | 0 | ||
2020-10-27 | 2020-09-30 | 0.16 | 0.24 | 0.08 | 50 | ||
2020-07-28 | 2020-06-30 | 0.09 | 0.2 | 0.11 | 122 | ||
2020-04-28 | 2020-03-31 | 0.04 | 0.11 | 0.07 | 175 | ||
2020-02-13 | 2019-12-31 | 0.18 | 0.29 | 0.11 | 61 | ||
2019-11-06 | 2019-09-30 | 0.05 | 0.16 | 0.11 | 220 | ||
2019-07-31 | 2019-06-30 | 0.01 | 0.02 | 0.01 | 100 | ||
2019-05-01 | 2019-03-31 | -0.04 | -0.01 | 0.03 | 75 | ||
2019-02-21 | 2018-12-31 | 0.04 | 0.14 | 0.1 | 250 | ||
2018-11-06 | 2018-09-30 | -0.02 | 0.04 | 0.06 | 300 | ||
2018-08-01 | 2018-06-30 | -0.05 | -0.02 | 0.03 | 60 | ||
2018-05-02 | 2018-03-31 | -0.08 | -0.08 | 0.0 | 0 | ||
2018-02-27 | 2017-12-31 | 0.01 | 0.03 | 0.02 | 200 | ||
2017-11-01 | 2017-09-30 | -0.04 | -0.01 | 0.03 | 75 | ||
2017-08-01 | 2017-06-30 | -0.05 | -0.04 | 0.01 | 20 | ||
2017-05-02 | 2017-03-31 | -0.13 | -0.12 | 0.01 | 7 | ||
2017-02-28 | 2016-12-31 | -0.02 | -0.02 | 0.0 | 0 | ||
2016-11-01 | 2016-09-30 | -0.03 | -0.05 | -0.02 | 66 | ||
2016-08-02 | 2016-06-30 | -0.03 | -0.06 | -0.03 | 100 | ||
2016-04-27 | 2016-03-31 | -0.05 | -0.06 | -0.01 | 20 | ||
2016-02-23 | 2015-12-31 | 0.01 | 0.01 | 0.0 | 0 | ||
2015-08-05 | 2015-06-30 | -0.01 | -0.01 | 0.0 | 0 | ||
2015-04-29 | 2015-03-31 | -0.03 | -0.04 | -0.01 | 33 | ||
2015-02-25 | 2014-12-31 | -0.01 | 0.01 | 0.02 | 200 | ||
2014-11-06 | 2014-09-30 | -0.01 | -0.02 | -0.01 | 100 | ||
2014-08-06 | 2014-06-30 | -0.03 | -0.02 | 0.01 | 33 | ||
2014-05-01 | 2014-03-31 | -0.02 | -0.04 | -0.02 | 100 | ||
2014-02-20 | 2013-12-31 | -0.02 | -0.01 | 0.01 | 50 | ||
2013-11-06 | 2013-09-30 | -0.03 | -0.02 | 0.01 | 33 | ||
2013-08-07 | 2013-06-30 | -0.04 | -0.04 | 0.0 | 0 | ||
2013-05-01 | 2013-03-31 | -0.04 | -0.04 | 0.0 | 0 | ||
2013-02-21 | 2012-12-31 | -0.04 | -0.03 | 0.01 | 25 | ||
2012-11-01 | 2012-09-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2012-08-06 | 2012-06-30 | -0.05 | -0.05 | 0.0 | 0 | ||
2012-05-02 | 2012-03-31 | -0.05 | -0.05 | 0.0 | 0 | ||
2012-02-23 | 2011-12-31 | -0.04 | -0.04 | 0.0 | 0 | ||
2011-11-02 | 2011-09-30 | -0.04 | -0.05 | -0.01 | 25 | ||
2011-08-03 | 2011-06-30 | -0.03 | -0.03 | 0.0 | 0 | ||
2011-05-03 | 2011-03-31 | -0.05 | -0.05 | 0.0 | 0 | ||
2011-03-03 | 2010-12-31 | -0.05 | -0.04 | 0.01 | 20 | ||
2010-11-04 | 2010-09-30 | -0.04 | -0.06 | -0.02 | 50 | ||
2010-08-03 | 2010-06-30 | -0.05 | -0.05 | 0.0 | 0 | ||
2010-05-05 | 2010-03-31 | -0.06 | -0.07 | -0.01 | 16 | ||
2010-03-09 | 2009-12-31 | -0.07 | -0.06 | 0.01 | 14 | ||
2009-11-04 | 2009-09-30 | -0.08 | -0.07 | 0.01 | 12 | ||
2009-08-03 | 2009-06-30 | -0.08 | -0.08 | 0.0 | 0 | ||
2009-05-06 | 2009-03-31 | -0.08 | -0.08 | 0.0 | 0 | ||
2009-03-05 | 2008-12-31 | -0.11 | -0.11 | 0.0 | 0 | ||
2008-11-10 | 2008-09-30 | -0.12 | -0.12 | 0.0 | 0 | ||
2008-08-05 | 2008-06-30 | -0.11 | -0.12 | -0.01 | 9 | ||
2008-05-08 | 2008-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2008-03-11 | 2007-12-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2007-10-30 | 2007-09-30 | -0.1 | -0.1 | 0.0 | 0 | ||
2007-07-30 | 2007-06-30 | -0.1 | -0.1 | 0.0 | 0 | ||
2007-05-09 | 2007-03-31 | -0.1 | -0.1 | 0.0 | 0 | ||
2007-02-27 | 2006-12-31 | -0.12 | -0.1 | 0.02 | 16 | ||
2006-10-23 | 2006-09-30 | -0.1 | -0.12 | -0.02 | 20 | ||
2006-07-20 | 2006-06-30 | -0.11 | -0.1 | 0.01 | 9 | ||
2006-05-15 | 2006-03-31 | -0.12 | -0.11 | 0.01 | 8 | ||
2006-02-27 | 2005-12-31 | -0.07 | -0.12 | -0.05 | 71 | ||
2005-11-01 | 2005-09-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2005-08-02 | 2005-06-30 | -0.06 | -0.07 | -0.01 | 16 |
About DexCom Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of DexCom earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current DexCom estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as DexCom fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | 1.8 B | 1.9 B | |
| Retained Earnings Total Equity | 551.9 M | 579.5 M | |
| Earnings Yield | 0.02 | 0.02 | |
| Price Earnings Ratio | 49.15 | 51.61 | |
| Price Earnings To Growth Ratio | 35.39 | 37.16 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.099 | Earnings Share 1.78 | Revenue Per Share | Quarterly Revenue Growth 0.216 | Return On Assets |
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value - what DexCom's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.